Riskpilot← Back to searchSign inGet full accessPharmia Oy
OYActiveY-tunnus 2087243-9Kalliotie 2Manufacture of pharmaceutical preparations · NACE 2120Est. 2007— employeespharmia.fi
Revenue 2025
EUR 199
+12% vs 2024
EBITDA margin
479810.6%
-64% vs 2024
Equity ratio
54.7%
Financial strength
Net profit 2025
EUR 11
+83% vs 2024
| Revenue | EUR 199 | +12% |
| EBITDA | EUR 955K | -64% |
| Net profit | EUR 11 | +83% |
| Total assets | EUR 14,8M | +11% |
| Equity | EUR 8,1M | +14% |
| Employees | — | — |
Legal name
Pharmia Oy
Y-tunnus number
2087243-9
Legal form
Osakeyhtiö
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
11. tammikuuta 2007
Share capital
EUR 3 000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on elintarvikkeiden ja lääketieteellisten laitteiden tuotekehitys, valmistus ja markkinointi samoin kuin näihin liittyvä sekä hyvinvointialan konsultoinnin että palvelujen myynti ja sijoitustoiminta.
Address
Kalliotie 2
Phone
+358098254030
Website
pharmia.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 15 786 | 17 627 | 0 | 0 | 0 |
| Staff expenses | −4 606 | −4 876 | −5 284 | −4 943 | −5 466 |
| EBITDA | 2 613 | 2 376 | 622 | 2 640 | 955 |
| Depreciation & amort. | −674 | −692 | −622 | −731 | −955 |
| EBIT | 1 939 | 1 684 | 0 | 1 909 | 0 |
| Net financials | −151 | −94 | −939 | −221 | −217 |
| Profit before tax | 1 788 | 505 | −939 | 647 | 1 113 |
| Tax | 378 | 319 | −53 | 647 | 0 |
| Net profit | 1 410 | 186 | 0 | 0 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 13 512 | 15 779 | 13 087 | 13 372 | 14 839 |
| Equity | 7 599 | 7 419 | 6 070 | 7 110 | 8 121 |
| Long-term debt | 3 206 | 5 150 | 3 917 | 3 007 | 3 527 |
| Short-term debt | 2 707 | 3 210 | 2 692 | 2 847 | 2 783 |
| Total debt | 5 913 | 8 361 | 6 609 | 5 854 | 6 310 |
EBITDA margin
479810.6%
This company
15.8%
Market median
+3036676% vs market
20212025
Equity ratio
54.7%
This company
38.2%
Market median
+43% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
5.5%
This company
8.1%
Market median
-32% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.83×
This company
0.62×
Market median
+34% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EJ Confidential Clerk | Confidential Clerk | 2022 |
| Former (4) | ||
PB Audit | Audit | 2021 – 2023 |
JK | Audit | 2007 – 2021 |
HJ Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
JT Chief Executive Officer | Chief Executive Officer | 2018 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Chairperson | 2025 | |
| Board of Directors | 2025 | |
| Former (11) | ||
| Board of Directors | 2019 – 2021 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2021 – 2025 | |
| Chairperson | 2021 – 2025 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2025 – 2025 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2021 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharmia Holding Oy
Pharmia Oy Board members of Pharmia Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eero Juhani Huhta | Confidential Clerk | 0 companies |
| Peter Birger Åhman | Audit | 0 companies |
| Joakim Kristoffer Rehn | Audit | 0 companies |
| Hannu Juha Tapio Vakkari | Chief Executive Officer | 0 companies |
| Janne Tapani Kostamo | Chief Executive Officer | 0 companies |
| Riitta Helena Huuhtanen | Board of Directors | 0 companies |
| Pauliina Satu Sinikka Seeck | Board of Directors | 0 companies |
| Anders Viking Björkell | Board of Directors | 0 companies |
| Pekka Mikael Kaivola | Chairperson | 0 companies |
| Kaisa Tarkkanen | Board of Directors | 0 companies |
| Jaakko Sakari Rissanen | Board of Directors | 0 companies |
| Zacharias Veli Matias Harmia | Board of Directors | 0 companies |
| Suvi Saara Maria Pulkkinen | Board of Directors | 0 companies |
| Ninni Aleksandra Katriina Hietaniemi-Penttinen | Board of Directors | 0 companies |
| Kari Juhani Pulkkinen | Board of Directors | 0 companies |
| Hans Petteri Laaksomo | Board of Directors | 0 companies |
| Luciano Marton | Chairperson | 0 companies |
| Marco Malaguti | Board of Directors | 0 companies |
| Antti Lauri Sakari Karppinen | Board of Directors | 0 companies |